Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center.

Crinecerfont and Classic CAH: 2-Year CAHtalyst Results, With Oksana Hamidi, DO

Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency requires lifelong glucocorticoid replacement to suppress adrenocorticotropic hormone (ACTH) and control adrenal androgen excess. The fundamental clinical challenge is that achieving androgen control typically demands supraphysiologic glucocorticoid doses, which carry substantial toxicity. Patients are at risk for exogenous Cushing syndrome, cardiometabolic complications, and reduced quality of life from high-dose, multi-daily regimens.

00:02:29 - Discontinuation of Dexamethasone, Hydrocortisone Reduction

00:03:58 - Long-Term Adherence and Tolerability

00:04:54 - Impact on Downstream CAH Effects

The physiologic replacement range for hydrocortisone is approximately 15 to 20 mg/day, yet many adults with classic CAH are managed on doses nearly double that threshold.

Crinecerfont, a first-in-class corticotropin-releasing factor type 1 (CRF1) receptor antagonist, offers a mechanistically distinct approach. By blocking CRF from activating the CRF1 receptor, crinecerfont reduces ACTH drive and adrenal androgen production, potentially enabling GC dose reduction without sacrificing androgen control. In December 2024, the agent received US Food and Drug Administration approval as an adjunct to physiologic glucocorticoid replacement in classic CAH.

2-year data from the CAHtalyst Adult Study presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 by Oksana Hamidi, DO, an associate professor in the division of endocrinology and metabolism at the University of Texas Southwestern Medical Center, extend previously reported findings supporting the FDA approval. The trial enrolled 182 adults taking supraphysiologic glucocorticoid doses at baseline, with a mean daily dose of approximately 32 mg/day. By week 24, crinecerfont-treated participants achieved a least-squares mean glucocorticoid reduction of 27% versus 10% with placebo (LSMD, -17%; 95% CI, -24% to -10%; 

Results showed that reduction was sustained through month 24, with mean glucocorticoid doses stabilizing at approximately 19.4 mg/day (10.6 mg/m²/day). Of note, the proportion of participants achieving a glucocorticoid dose within the physiologic range held at approximately 70% from month 12 through month 24.

Reductions in treatment burden were also documented. Among patients on hydrocortisone with > 2 doses per day, 62% reduced their dosing frequency by ≥ 1 dose per day. Of those on dexamethasone-containing regimens, 75% became dexamethasone-free. Cumulatively, actual glucocorticoid exposure over 2 years was 8010 mg/m² versus a projected 12,152 mg/m² had patients remained on their baseline dose.

“Patients who have classic CAH oftentimes require multiple medications per day, multiple doses per day, so it is a big challenge for them to live on a clock and constantly have reminders on their watches and calendars to keep taking their glucocorticoids, otherwise they lose control of their androgens,” Hamidi explained. “By reducing the doses, say, from 3 times a day dosing to 2 times a day dosing, I strongly believe that that improves patients' overall quality of life, but also their sense about their disease control and allows them to be more consistent with their medication.”

Safety data across the full 2-year period showed no new signals, with most adverse events rated mild or moderate and few discontinuations. Hamidi noted that as glucocorticoid doses are lowered, clinicians should ensure patients are equipped with sick-day guidance and injectable glucocorticoids for adrenal crisis prevention.

The trial's retention rate of > 80% over 2 years reflects sustained patient engagement that Hamidi described as exceeding her expectations and as evidence that patients were seeing the outcomes they had hoped for.

Editors’ note: Hamidi reports relevant disclosures with Corcept Therapeutics, Neurocrine Biosciences, Adaptyx, Camurus, Crinetics Pharmaceuticals, and Recordati Rare Diseases, Inc.

Iapoce C. FDA Approves Crinecerfont for Congenital Adrenal Hyperplasia. HCPLive. December 13, 2024. Accessed April 24, 2026. 

https://www.hcplive.com/view/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia

Bancos I, Hamidi O, Kiefer FW, et al. Adults With Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

Videos

Hamidi reviews 2-year CAHtalyst data showing crinecerfont enabled sustained glucocorticoid reductions to physiologic range in adults with classic congenital adrenal hyperplasia.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

CAHtalyst Adult: Sustained GC Reduction With Crinecerfont in CAH, With Oksana Hamidi, DO

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Triple therapy with budesonide–glycopyrronium–formoterol fumarate (BGF) was associated with statistically significant improvements in lung function and reductions in severe exacerbations among patients with 

 despite inhaled corticosteroid–long-acting β2-agonist (ICS–LABA) therapy, according to results from the phase 3 KALOS and LOGOS trials.

Current Global Initiative for Asthma (GINA) recommendations support escalation to triple therapy with ICS–LABA–LAMA in patients with uncontrolled disease at step 5, particularly those with exacerbation risk.

 However, real-world uptake and optimal patient selection remain areas of ongoing investigation.

Alberto Papi, MD, from the University of Ferrara in Italy, Robert A. Wise, MD, from Johns Hopkins University, and colleagues conducted the KALOS and LOGOS trials: 2 multicenter, randomized, double-blind, double-dummy, parallel-group phase 3 studies enrolling patients aged 12 to 80 years with asthma inadequately controlled on medium- or high-dose ICS–LABA therapy.

 Participants were randomized to receive 1 of 4 regimens: BGF 320/28.8/10 μg, BGF 320/14.4/10 μg, budesonide–formoterol fumarate dihydrate via Aerosphere (BFFA), or budesonide–formoterol suspension (BFFS), administered twice daily for 24 to 52 weeks via a pressurized metered-dose inhaler.

A total of 8820 participants were recruited across both trials, with 4311 receiving treatments. The primary endpoints included changes from baseline in FEV₁ area under the curve over 0–3 hours (AUC₀–₃) and morning pre-dose trough forced expiratory volume in 1 second(FEV₁) over 24 weeks, as well as pooled annualized severe exacerbation rates.

Across the pooled analysis, BGF demonstrated superiority over dual therapy comparators in both FEV₁ measures and annualized exacerbation rates.

 These findings support the addition of a long-acting muscarinic antagonist (LAMA) in patients with persistent symptoms and may inform treatment escalation strategies.

BGF 320/28.8/10 μg met all multiplicity-adjusted primary endpoints. Compared with combined dual therapy comparators, BGF improved trough FEV₁ by 76 mL (95% CI, 57–94; 

<.0001) and FEV₁ AUC₀–₃ by 90 mL (95% CI, 72–108; 

<.0001). In pooled analyses, BGF reduced severe exacerbation rates versus combined budesonide–formoterol comparators (incidence rate ratio [IRR], 0.86; 95% CI, 0.76–0.97; 

=.012) and versus BFFS alone (IRR, 0.82; 95% CI, 0.71–0.94; 

=.0043). The reduction versus BFFA did not reach statistical significance (IRR, 0.90; 95% CI, 0.78–1.03; 

Adverse events were reported in 53.2% of patients receiving BGF 28.8 μg, compared with 55.2% to 60.0% across comparator groups. No treatment-related deaths were reported, and the overall safety profile was consistent with known effects of ICS–LABA and LAMA therapies.

The addition of a LAMA targets bronchoconstriction through muscarinic receptor antagonism, complementing the anti-inflammatory effects of ICS and bronchodilation from LABA. BGF combines budesonide (ICS), glycopyrronium (LAMA), and formoterol (LABA) in a pressurized metered-dose inhaler using co-suspension delivery technology. This formulation has previously been approved for chronic obstructive pulmonary disease (COPD) based on results from ETHOS and KRONOS.

 Its evaluation in asthma extends the potential role of this platform into a broader airway disease population.

Although statistically significant, the absolute improvements in FEV₁ were modest, and the clinical significance at the individual patient level may vary.

The trials included a broad population, which enhances generalizability but may obscure subgroup-specific effects, such as by eosinophilic phenotype or biomarker status. Additionally, the lack of statistically significant exacerbation reduction versus one comparator (BFFA) highlights the need for further comparative effectiveness data.

“Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS–LABA before escalation,” the team wrote.

Papi A, Wise RA, Jackson DJ, et al. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. 

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Update. Published 2022. Accessed on April 24, 2026. 

Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. 

Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. 

Articles

Twin phase 3 randomized trials (KALOS/LOGOS) evaluated budesonide–glycopyrronium–formoterol (BGF) in adolescents and adults with asthma uncontrolled on medium/high-dose ICS–LABA. Across pooled analyses, BGF 320/28.8/10 μg achieved multiplicity-adjusted co-primary lung-function endpoints and reduced annualized severe exacerbations versus pooled budesonide–formoterol comparators, with no new safety signals. Absolute FEV₁ gains were modest, and exacerbation reduction versus one dual-therapy comparator was not statistically significant, underscoring residual uncertainty around optimal patient selection.

Twin phase 3 trials show triple therapy with budesonide–glycopyrronium–formoterol improves FEV1 and lowers severe exacerbation rates in patients with uncontrolled asthma on ICS–LABA


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

BGF Triple Therapy Improves Lung Function in Phase 3 Uncontrolled Asthma Controls

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

Reviewing Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD

Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD

In a recent review, titled ‘Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipeline,’ Christopher G. Bunick, MD, PhD, and colleagues highlight a growing therapeutic gap in 

, emphasizing that many patients treated with current monospecific biologics fail to achieve optimal disease control.

Bunick, known for his role at the Yale School of Medicine, spoke about his team’s work in an interview with 

, noting atopic dermatitis is not driven by a single cytokine pathway, but rather a complex network, including interleukin (IL)-4, IL-13, IL-31, thymic stromal lymphopoietin (TSLP), interferon gamma, IL-22, and IL-17. This contributes to significant clinical and molecular heterogeneity and this complexity, Bunick et al argue, necessitates a shift toward multi-targeted approaches.

“I felt that this was a much needed topic to cover, because the innovation in atopic dermatitis is exploding,” Bunick expressed. “In particularly there's a lot of innovation around multi targeted agents.”

His team’s review outlines a rapidly expanding pipeline of bispecific and trispecific antibodies designed to simultaneously inhibit multiple inflammatory and neuroimmune pathways. Bunick and coauthors detailed how such next-generation biologics are designed to improve upon current medications by providing patients with more sustained skin clearance, better control of pruritus, and potentially longer dosing intervals.

They also reviewed advances in antibody engineering, including half-life extension technologies potentially enabling dosing intervals as infrequent as every 3 - 6 months, as well as Fc-region modifications to optimize safety and immune effects. Overall, the team positions multi-specific biologics as a promising strategy.

In his interview, Bunick expanded on these data, first acknowledging his co-authors’ contributions and noting that the review was developed in response to a surge of innovation in the atopic dermatitis treatment landscape. He emphasized that the central unmet need remains the inability of many patients to reach minimal disease activity with existing therapies, which typically target a single cytokine or receptor.

Bunick explained that this limitation stems directly from the heterogeneous biology of atopic dermatitis, where multiple cytokines and pathways drive both inflammation and symptom burden. While current agents such as IL-4/IL-13 or IL-31 inhibitors provide benefit, they do not fully address the breadth of disease drivers. As a result, emerging bispecific and trispecific therapies are being designed to simultaneously target two or more pathways to achieve more comprehensive disease control.

Bunick also noted the importance of mechanistic insights connecting immune signaling and neurobiology. Increasing evidence shows that cytokine receptors are expressed not only on keratinocytes and immune cells but also on sensory neurons, directly influencing itch. According to Bunick, effective treatment of atopic dermatitis will require addressing both inflammatory pathways and neuroimmune itch signaling. Such a dual-targeting approach is a key rationale behind many pipeline agents, especially those incorporating IL-31 or TSLP inhibition.

For any additional information, view Bunick’s interview segment posted above.

Bunick has reported receiving consultant fees or serving as an investigator for AbbVie, Incyte, LEO Pharma and Pfizer.

Amid-Toby G, Alani O and Bunick CG (2026) Bispecific and trispecific antibodies in atopic dermatitis: a review of the emerging clinical pipeline. Front. Drug Discov. 6:1766021. 

EichenfieldL.GradaA.KnappK.MunozB.CrawfordJ.SilverbergJ. (2024). Persistent inadequate disease control and therapeutic inertia in moderate-to-severe atopic dermatitis: a 12-month longitudinal analysis of real-world outcomes from the TARGET-DERM AD registry. SKIN J. Cutan. Med.8 (6), s462. 10.25251/skin.8.supp.462. 

Christopher Bunick, MD, PhD, and colleagues conducted a review bispecific and trispecific antibodies in atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Linda DiMeglio, MD, MPH, is a professor of pediatrics and the division chief at Indiana University School of Medicine.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: The Push for Early-Stage T1D Screening and Treatment, With Linda DiMeglio, MD, MPH

In this episode of Diabetes Dialogue recorded on-site at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, interview Linda DiMeglio, MD, MPH, professor of pediatrics and division chief at Indiana University School of Medicine, following her plenary keynote and receipt of the Ellen Garber Award. DiMeglio outlines her broad work in type 1 diabetes research, including prevention strategies, beta cell preservation, diabetes technology, TrialNet leadership, and neurocognitive studies in young children living with diabetes.

The discussion centers on early-stage type 1 diabetes, with DiMeglio reviewing the evolving framework of risk identification and staging, from genetic predisposition and single autoantibody positivity through stage 1, stage 2, and stage 3 disease. She highlights the growing momentum behind both general population and family-based screening, emphasizing the importance of early detection not only to prevent diabetic ketoacidosis but also to enable timely intervention with disease-modifying therapies. She notes the recent expansion of teplizumab approval down to age 1 for stage 2 disease as a major milestone and describes the broader therapeutic goal as ultimately ending insulin dependence for people living with type 1 diabetes.

DiMeglio and the hosts discuss how the field has shifted significantly over the past decade, particularly with the reframing of “cure” as a combination of multiple targeted approaches rather than a single intervention. She underscores the importance of combination immunotherapy strategies, citing recent TrialNet work using rituximab followed by abatacept, as well as the need for more personalized approaches based on individual disease etiology and immune characteristics. She also stresses the need for better intermediate endpoints beyond the traditional 2-year C-peptide model to accelerate therapeutic development and trial efficiency.

The group also examines the increasing role of patient and family perspectives in clinical trial design, particularly through TrialNet’s community advisory board, which DiMeglio believes will improve recruitment and trial execution. They discuss the broader implications of immune-modifying therapies in type 1 diabetes, including parallels with oncology treatment models and the potential for these advances to inform management strategies for other autoimmune diseases. DiMeglio also reflects on how these therapies are reshaping endocrinology practice itself, requiring clinicians to become more familiar with immunomodulation, cytokine management, and interdisciplinary care.

A major focus of the conversation addresses the complexity of autoantibody interpretation, particularly around GAD antibodies and low-titer positivity. DiMeglio emphasizes that a single positive islet autoantibody test should never be considered definitive and should always be repeated, ideally in a separate gold-standard laboratory such as TrialNet. She explains that antibody specificity varies by type and titer, with higher titers often offering greater diagnostic confidence, while acknowledging ongoing uncertainty around interpretation in adults, diverse populations, and long-standing diabetes. The hosts also discuss the practical challenges of coding, insurance coverage, and patient counseling as early-stage diabetes diagnosis becomes more common.

The episode concludes with a discussion of emerging questions around antibody fluctuation over time, circadian variation in antibody measurements, and the role of genetic screening. DiMeglio notes that antibody status may shift over years and may even vary by time of day, introducing additional complexity into monitoring strategies. While genetic risk screening remains promising, she explains that large-scale antibody-based population screening may currently be more practical from a public health perspective. She closes by reinforcing that although much remains nuanced and unresolved, the field is rapidly advancing toward earlier intervention, more individualized treatment, and a fundamentally different future for type 1 diabetes care.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. DiMeglio reports disclosures with Amgen, Lilly, Mannkind, Medtronic, Merck, Ascendis, and others.

DiMeglio L. Early-Stage Type 1 Diabetes: Screening, Monitoring, Treatments and Future Directions (Alan J. Garber, MD Lectureship). Presented at the American Association of Clinical Endocrinology Annual Meeting 2026, Las Vegas, NV. April 22-24, 2026.

Podcasts

Linda DiMeglio, MD, MPH, joins the show to discuss the growing movement towards screening and testing for T1D at an early stage.

Type 1 Diabetes

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

GLP-1 receptor agonists (GLP-1 RAs) have become among the most prescribed drug classes in modern endocrinology, reshaping the management of 

 through benefits extending beyond glycemic control, including cardiovascular risk reduction, renal protection, and weight loss.

 has remained largely uncharted. Despite the growing prevalence of obesity in the type 1 population, estimated at approximately 37% in recent data, GLP-1 RAs currently do not carry a US Food and Drug Administration approval for this indication, and type 1 diabetes was excluded from the pivotal trials underpinning their commercial approval.

GLP-1 receptor agonist use was not associated with increased rates of DKA or pancreatitis in adults with type 1 diabetes in this real-world, single-center cohort.

0 DKA or pancreatitis admissions were recorded among 255 type 1 diabetes patients on GLP-1 RA therapy over a 1-year period, compared to rates of 0.39% and 0.55%, respectively, in non-users.

GLP-1 RA users had a significantly lower overall hospital admission rate than non-users (7.45% vs. 13.11%; 

= .01), consistent with hospitalization reductions seen in type 2 diabetes outcome trials.

Chief among the concerns limiting off-label use has been the potential risk of diabetic ketoacidosis (DKA). In patients with type 1 diabetes, a population who depends entirely on exogenous insulin, there are concerns regarding the appetite-suppressing and gastric-slowing effects of GLP-1 RAs potentially prompting inappropriate reductions in insulin dosing and precipitating ketoacidosis. Pancreatitis has also been raised as a safety signal across the GLP-1 RA class.

However, without dedicated trial data in this population, clinicians prescribing these agents off-label have had little real-world evidence to guide risk counseling. New data presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 begin to address that gap.

Justin Do, DO, an endocrinology fellow at Loma Linda University Medical Center, presented findings from a retrospective, cross-sectional analysis of 7377 adults with type 1 diabetes seen at a single academic center between July 2024 and July 2025. The primary outcome was hospital admission for DKA or pancreatitis based on ICD-10 coding.

Of the included patients, 255 were on a GLP-1 RA, either semaglutide (n = 167), tirzepatide (n = 60), dulaglutide (n = 19), or liraglutide (n = 9). Patients in the GLP-1 RA group were older on average (mean age 45 vs 37 years), had higher mean BMI (33.4 vs 26.6 kg/m²), and were predominantly female (65.2%).

Among GLP-1 RA users, there were 0 admissions for either DKA or pancreatitis during the study period. In the non-GLP-1 group, DKA admission rates were 0.39% and pancreatitis admissions were 0.55%, although investigators noted neither difference reached statistical significance (

= .64, respectively). Overall hospital admission rate was investigated as an exploratory finding of potential clinical relevance, which was significantly lower in GLP-1 RA users compared to non-users (7.45% vs 13.11%l χ²=6.52; 

However, investigators acknowledged meaningful limitations, including the retrospective, single-center design limiting generalizability and the relatively small GLP-1 RA cohort potentially being underpowered to detect rare events. Additionally, dosing and duration of GLP-1 RA therapy were not captured, and the study relied on ICD-10 coding rather than chart-confirmed diagnoses. Selection bias is also a concern, as patients prescribed GLP-1 RAs off-label may represent a more closely monitored or metabolically managed subset of the type 1 population.

“GLP-1 RA therapy may offer meaningful clinical benefit in adults with type 1 diabetes,” Do and colleagues wrote. “However, further studies are warranted in this population.”

Resnick O, Bril F, Beauchamp G. Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?. Front Endocrinol (Lausanne). 2025;15:1520313. Published 2025 Jan 21. doi:10.3389/fendo.2024.1520313

Do J, Seidel V, Hassan B. Diabetic Ketoacidosis and Safety Outcomes with GLP-1 Agonists in Type 1 Diabetes Mellitus. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

GLP-1 receptor agonists have transformed type 2 diabetes care, yet their use in type 1 diabetes remains off-label amid concerns for DKA and pancreatitis, particularly if insulin is inappropriately reduced. A retrospective single-center analysis of 7377 adults with type 1 diabetes identified 255 GLP-1 RA users, predominantly semaglutide or tirzepatide, who were older with higher BMI. No DKA or pancreatitis admissions occurred among GLP-1 RA users, and overall hospitalization was lower versus non-users, despite important methodological limitations.

New real world data suggest GLP-1 RAs do not drive DKA or pancreatitis risk in adult patients with type 1 diabetes and may reduce hospital admissions.

GLP-1 RAs Do Not Raise Diabetic Ketoacidosis, Pancreatitis Risk in Type 1 Diabetes

Shah discusses the potential of GLP-1 receptor agonists as adjunctive therapy in type 1 diabetes, from glycemic control to cardiometabolic risk.

Beyond Insulin: Evaluating GLP-1 RAs as Adjunctive Therapy in Type 1 Diabetes, With Viral Shah, MD

Jeffrey Mechanick, MD, is the medical director of the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Fuster Heart Hospital and a professor of medicine at the Icahn School of Medicine at Mount Sinai.

Mechanick discusses the importance of dietary interventions in endocrinology and highlights the need for further education and awareness of metabolic function.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Reemphasizing Nutrition and Diet in Managing Chronic Endocrine Disease, With Jeffrey Mechanick, MD

Yun Liu, PhD, is a senior staff research scientist at Google Health/Research, focused on developing and validating machine learning models for medical imaging, including pathology, dermatology, and ophthalmology.

In this segment of the interview, questions remaining about AI's effectiveness among patients in dermatology were explored.

Are Improvements in AI Needed for Dermatology Patients? With Rory Sayres, PhD, and Yun Liu, PhD

Rodolfo Galindo, MD, is an Associate Professor of Medicine at the University of Miami, and Director of the Comprehensive Diabetes Center of UHealth and the Director of Diabetes Management for Jackson Health System, in Miami.

Galindo describes how CKM may transform diabetes care by enabling real-time insights, improving DKA prevention, and advancing metabolic understanding.

Continuous Ketone Monitoring in Diabetes: Clinical Potential and Future Impact, With Rodolfo Galindo, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

FDA approved lunsotogene parvec for OTOF-related hearing loss based on phase 1/2 data showing improved hearing in a small cohort.

FDA News

FDA Approves Lunsotogene Parvec for OTOF-Related Genetic Hearing Loss

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Recent data presented at AACE 2026 have indicated the efficacy of GLP-1 RA treatment in reducing risk of diabetic retinopathy, renal disease, and others.

GLP-1 RAs Improve End-Organ Complications in Patients With Type 1 Diabetes

Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

Guidance for Clinicians on Patient Questions About Psychedelics, With Gus Alva, MD

Rory Sayres, PhD, is a researcher in the Health AI group in Google Research who focuses on intelligence augmentation of medical experts using machine-learning-based assistance.

Liu and Sayres emphasize that while AI tools improve consumer recognition of skin conditions, gaps remain in prediction accuracy and information.

Patient Awareness of Dermatologic Conditions Using AI, With Rory Sayres, PhD, and Yun Liu, PhD

A recent study presented at AACE 2026 has displayed the IGF-1R’s capacity for improving proptosis and disease activity in patients with poorly-controlled TED.

Thyroid Disorders

IBI311 Efficacious and Safe in Reducing Proptosis in Thyroid Eye Disease

Learn how Leipzig scoring and genetic testing, plus labs and eye exams, help diagnose pediatric Wilson disease when symptoms are subtle.

Latest News

CAHtalyst Adult: Sustained GC Reduction With Crinecerfont in CAH, With Oksana Hamidi, DO

BGF Triple Therapy Improves Lung Function in Phase 3 Uncontrolled Asthma Controls

Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD

Diabetes Dialogue: The Push for Early-Stage T1D Screening and Treatment, With Linda DiMeglio, MD, MPH

GLP-1 RAs Do Not Raise Diabetic Ketoacidosis, Pancreatitis Risk in Type 1 Diabetes